<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Collagenopathies with collagen VI mutations include Ullrich <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo> (<z:e sem="disease" ids="C0410179" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Ullrich's disease</z:e>) and Bethlem <z:hpo ids='HP_0003198'>myopathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with <z:e sem="disease" ids="C0410179" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Ullrich's disease</z:e> have <z:hpo ids='HP_0003324'>generalized muscle weakness</z:hpo>, multiple <z:hpo ids='HP_0001371'>contractures</z:hpo> of the proximal joints and hyperextensibility of the distal joints </plain></SENT>
<SENT sid="2" pm="."><plain>Bethlem <z:hpo ids='HP_0003198'>myopathy</z:hpo> is characterized by the combination of <z:hpo ids='HP_0003701'>proximal muscle weakness</z:hpo> and <z:hpo ids='HP_0001371'>contractures</z:hpo> of finger, elbow, and ankle joints </plain></SENT>
<SENT sid="3" pm="."><plain>We found for the first time a deficiency of collagen VI in <z:e sem="disease" ids="C0410179" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Ullrich's disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, we found an abnormality of cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and abnormal regeneration or maturation in <z:e sem="disease" ids="C0410179" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Ullrich's disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Mutations in the genes COL6A1, COL6A2, COL6A3 are associated with <z:e sem="disease" ids="C0410179" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Ullrich's disease</z:e> and Bethlem <z:hpo ids='HP_0003198'>myopathy</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Bethlem <z:hpo ids='HP_0003198'>myopathy</z:hpo> is inherited in an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> manner and <z:e sem="disease" ids="C0410179" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Ullrich's disease</z:e> usually in an <z:hpo ids='HP_0000007'>autosomal recessive</z:hpo> manner </plain></SENT>
<SENT sid="7" pm="."><plain>Recently, de novo dominant mutations are reported in <z:e sem="disease" ids="C0410179" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Ullrich's disease</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>We evaluated the role of nonsense-mediated <z:chebi fb="2" ids="33699">mRNA</z:chebi> decay (NMD) in <z:e sem="disease" ids="C0410179" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Ullrich's disease</z:e> that has a frameshift mutation with a premature termination codon in the COL6A2 gene causing the loss of collagen VI </plain></SENT>
<SENT sid="9" pm="."><plain>The pharmacological block of NMD caused upregulation of the mutant collagen VI and partially functional extracellular matrix formation </plain></SENT>
<SENT sid="10" pm="."><plain>Our results suggest that NMD inhibitors can be used as a therapeutic tool to rescue some human <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic diseases</z:e> exacerbated by NMD </plain></SENT>
</text></document>